Clinical Trial Update: Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM) [Phase 1, Phase 2]

View source ↗

Summary

This document reports the completion of a Phase 1/2 study evaluating Vorinostat in combination with Bortezomib, Doxorubicin, and Dexamethasone (VBDD) in patient…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• DEXAMETHASONE (Dexamethasone)
• Doxorubicin (doxorubicin)
• Vorinostat (vorinostat)

Snippet

Sponsor: University Hospital Freiburg | Conditions: Multiple Myeloma in Relapse | Phase 1, Phase 2 | Status: COMPLETED